CD33 and acute myeloid leukemia: CD16 × IL-15 × CD33 TriKE displayed markedly enhanced NK cytotoxicity against AML and better NK cell persistence than did BiKE CD16 × CD33 in vivo, because the TriKE provided NK cell expansion signal via IL-15 moiety.